Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Telo Genomics Corp (3D0A) Stock Price & Analysis

0 Followers

3D0A Stock Chart & Stats

€0.02€0.00(20.00%)
At close: 5:30 PM GMT+1
€0€0.1€0.2€0.3Apr 8Feb 13Apr 11Jun 16
Day’s Range
EUR 0.02 - EUR 0.04
52-Week Range
EUR 0.00 - EUR 0.04
Previous Close
EUR 0.02
Volume
N/A
Average Volume (3M)
37
Market Cap
EUR 3.20M
Enterprise Value
EUR 5.86M
Total Cash (Recent Filing)
EUR 338.32K
Total Debt (Recent Filing)
EUR 1.44M
Price to Earnings (P/E)
―
Beta
-17.20
Next Earnings
Nov 19, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Diagnostic Platform Focus

The TeloView platform gives Telo Genomics a defined technological focus in telomere biology, with potential applications across oncology and hematology. A specialized diagnostic platform can support differentiated clinical and research offerings if the company converts its technology into validated, commercially adopted tests.

Improving Cash Burn

The reduction in operating and free cash outflows indicates some improvement in cost control or operating efficiency, even though the company remains loss-making. If maintained, a lower burn rate could extend financial runway and reduce the pace at which external capital is required while commercialization develops.

Losses Stopped Worsening

A modest reduction in net losses suggests the company may be moving toward greater operating discipline after several years of deterioration. While this is not evidence of profitability, stabilizing losses can preserve resources and provide a more manageable base for future revenue growth and commercialization efforts.

Bears Say

No Reported Revenue

The absence of reported revenue across six annual periods indicates that Telo Genomics has not yet demonstrated commercial traction from its diagnostic platform. This leaves the business dependent on future product adoption and creates substantial uncertainty around the timing and scale of eventual revenue generation.

Negative Equity And Rising Debt

Negative equity combined with newly increased debt materially weakens the company’s financial cushion. The more leveraged capital structure reduces flexibility to absorb operating setbacks, fund development internally, or withstand delays in commercialization, making future financing increasingly important to business continuity.

Persistent Cash Dependence

Although cash burn improved in 2026, the company continues to consume cash because operations generate no reported revenue and remain loss-making. Continued reliance on external funding can constrain strategic choices, increase financing pressure, and expose the business to disruption if capital is not available on acceptable terms.

Telo Genomics Corp News

3D0A FAQ

What was Telo Genomics Corp’s price range in the past 12 months?
Telo Genomics Corp lowest stock price was €0.00 and its highest was €0.04 in the past 12 months.
What is Telo Genomics Corp’s market cap?
Telo Genomics Corp’s market cap is €3.20M.
When is Telo Genomics Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Telo Genomics Corp’s earnings last quarter?
Telo Genomics Corp released its earnings results on Jun 02, 2026. The company reported -€0.004 earnings per share for the quarter.
Is Telo Genomics Corp overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Telo Genomics Corp pay dividends?
Telo Genomics Corp does not currently pay dividends.
What is Telo Genomics Corp’s EPS estimate?
Telo Genomics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telo Genomics Corp have?
Telo Genomics Corp has 100,222,720 shares outstanding.
What happened to Telo Genomics Corp’s price movement after its last earnings report?
Telo Genomics Corp reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of Telo Genomics Corp?
Currently, no hedge funds are holding shares in DE:3D0A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology